LLY
Eli Lilly and Company
LLY's fundamentals are strong: revenue grew 46% and it turned 23% of its revenue into free cash flow. At 46x earnings, it's trading in line with its usual 48x. Analysts expect that strong growth to continue.
PAVM
PAVmed Inc.
There isn't enough reported data to score PAVM yet.
LLY Fundamentals
| Metric | Status |
|---|---|
| Healthy | |
| Strong | |
| Strong | |
| Healthy |
LLY's revenue, profitability, cash flow and balance sheet are all currently healthy.
PAVM Fundamentals
| Metric | Status |
|---|---|
| Weak | |
| Weak | |
| Under pressure | |
| Unavailable |
PAVM's revenue, profitability and cash flow are currently under pressure. There isn't enough data to rate its balance sheet.
LLY PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Cheap | 27x | $845 | -41% |
| Forward | 30x | $1,427 | — |
| Current | 46x | $1,427 | — |
| Fair | 48x | $1,466 | +2.7% |
| Expensive | 85x | $2,612 | +83% |
Historical ranges are pointers, not guarantees.
LLY's PE is in its fair range at 46x. If earnings grow as analysts expect, today's price would be 30x next year's earnings, in its cheap range.
PAVM PE Valuation
PAVM has no meaningful PE right now: it lost money over the past year.
LLY Forward outlook
| Metric | Outlook |
|---|---|
| Strongly improving | |
| Strong growth | |
| Strong growth | |
| Strongly improving | |
| Limited | |
| Moderate |
Analysts expect strong earnings and revenue growth for LLY, with profitability improving.
PAVM Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Losses shrinking | |
| Strong growth | |
| -- | |
| Limited | |
| Low |
Analysts expect PAVM's losses to shrink, with revenue growing. However, they disagree widely on these estimates.
LLY Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $46.82 | +52% |
| Q3 2026 | $30.81 | +51% |
| Q2 2026 | $29.80 | +95% |
| Q1 2026 | $28.15 | +129% |
| Q4 2025 | $22.95 | +96% |
| Q3 2025 | $20.44 | +121% |
| Q2 2025 | $15.30 | +88% |
| Q1 2025 | $12.29 | +81% |
| Q4 2024 | $11.71 | +102% |
LLY has the stronger earnings trend. Trailing diluted EPS is up 51% for LLY versus PAVM down 107%.
PAVM Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q3 2024 | -$129.90 | +$189.83 |
| Q2 2024 | -$245.10 | +$133.13 |
| Q1 2024 | -$272.40 | +$173.33 |
| Q4 2023 | -$274.80 | +$179.93 |
| Q3 2023 | -$319.73 | +$134.77 |
| Q2 2023 | -$378.23 | +$13.27 |
| Q1 2023 | -$445.73 | -$121.73 |
| Q4 2022 | -$454.73 | -$162.23 |
PAVM is still losing money, but far less than before: $16.54 per share over the past year, against $454.73 at its worst in late 2022.
LLY Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $24.4B | +39% |
| Q2 2026 | $23B | +48% |
| Q1 2026 | $19.8B | +56% |
| Q4 2025 | $19.3B | +43% |
| Q3 2025 | $17.6B | +54% |
| Q2 2025 | $15.6B | +38% |
| Q1 2025 | $12.7B | +45% |
| Q4 2024 | $13.5B | +45% |
LLY has the edge over PAVM on sales, with more consistent year-over-year improvement.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 34% | -6.6 points |
| Q2 2026 | 40% | -3.3 points |
| Q1 2026 | 45% | +18 points |
| Q4 2025 | 43% | +5.6 points |
| Q3 2025 | 41% | +27 points |
| Q2 2025 | 44% | +12 points |
| Q1 2025 | 27% | -1.8 points |
| Q4 2024 | 37% | +10 points |
LLY has the edge over PAVM on profitability, with a higher operating margin.
PAVM Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q2 2026 | $33K | +450% |
| Q1 2026 | $22K | +175% |
| Q3 2025 | $5K | -100% |
| Q2 2025 | $6K | -99% |
| Q1 2025 | $8K | -99% |
| Q3 2024 | $1M | +26% |
| Q2 2024 | $1M | +502% |
| Q1 2024 | $1M | +124% |
PAVM's revenue is recovering but still below its 2023 peak: $33,000 last quarter, up 450% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q2 2026 | -21279% | +57305 points |
| Q1 2026 | -36523% | +31552 points |
| Q4 2025 | -13083% | N/A |
| Q3 2025 | -96880% | -95722 points |
| Q2 2025 | -78583% | -77215 points |
| Q1 2025 | -68075% | -66671 points |
| Q3 2024 | -1158% | +805 points |
| Q2 2024 | -1368% | +8562 points |
PAVM's operating margin was −21279% last quarter, up 57305 points from the same quarter a year ago.
LLY Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $8.2B | +22% |
| Q2 2026 | $7.8B | +458% |
| Q1 2026 | $3B | +1826% |
| Q4 2025 | $677.9M | -31% |
| Q3 2025 | $6.7B | +186% |
| Q2 2025 | $1.4B | +476% |
| Q1 2025 | $156.1M | -13% |
| Q4 2024 | $977.8M | +$2.4B |
LLY has the edge over PAVM on cash generation, producing positive trailing cash flow while its opponent burns cash.
PAVM Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q2 2026 | -$2.7M | -$1.5M |
| Q1 2026 | -$2.6M | -$1.1M |
| Q4 2025 | -$1.6M | -1839% |
| Q3 2025 | -$899K | +$8M |
| Q2 2025 | -$1.2M | +$10.5M |
| Q1 2025 | -$1.6M | +$11.6M |
| Q4 2024 | $90K | +$12.1M |
| Q3 2024 | -$8.9M | +$2.2M |
PAVM has burned cash in almost every quarter: −$8M over the past year, against −$12M the year before.
LLY Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | 0% | -300K shares |
| 1 year | -0.6% | -5.4M shares |
| 3 years | -0.7% | -6.4M shares |
| 5 years | -1.9% | -17.4M shares |
| Available history | -4.5% | -42.3M shares |
LLY has the edge over PAVM on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q3 2026 | $377M |
| Q2 2026 | $1.6B |
| Q1 2026 | $2.4B |
| Q4 2025 | $1.5B |
| Q3 2025 | $708.1M |
| Q2 2025 | $692.2M |
| Q1 2025 | $1.2B |
| Q4 2024 | $2.1B |
LLY spent $5.8B buying back its own shares over the past year, up 26% from the year before.
PAVM Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +297% | +4.7M shares |
| 1 year | +940% | +5.7M shares |
| 3 years | +3067% | +6.1M shares |
| 5 years | +5731% | +6.2M shares |
| Available history | +8992% | +6.2M shares |
PAVM has 6M diluted shares, up 940% from a year ago.
| Quarter | Spent |
|---|---|
| Q4 2019 | — |
LLY Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | 1.2x | Healthy |
| Q2 2026 | 1.3x | Healthy |
| Q1 2026 | 1.2x | Healthy |
| Q4 2025 | 1.3x | Healthy |
| Q3 2025 | 1.3x | Healthy |
| Q2 2025 | 2.0x | Healthy |
| Q1 2025 | 2.3x | Moderate |
| Q4 2024 | 2.1x | Moderate |
LLY's net debt is about 1.2 years of its operating earnings (EBITDA), about the same as a year ago.
PAVM Net Leverage
PAVM's operating earnings (EBITDA) were negative over the past year, so its debt can't be measured against them.
LLY Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 68.3 | Neutral |
| Stochastic | 84.1 | Overbought |
LLY's weekly RSI is 68 (neutral) and its Stochastic is 84 (overbought).
PAVM Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 21.8 | Oversold |
| Stochastic | 2.5 | Oversold |
PAVM's weekly RSI is 22 (oversold) and its Stochastic is 3 (oversold).
LLY PE vs Healthcare Sector
| Metric | LLY | Sector median | Relative |
|---|---|---|---|
| PE | 46x | 26x | 79% above |
| PE % | 48 | 29 | 19 pts above |
LLY is trading at 46x earnings, a 79% premium to the Healthcare sector's median of 26x.
PAVM PE vs Healthcare Sector
PAVM has no meaningful PE right now: it lost money over the past year.
LLY Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $1,279.4 | 12% above |
| 20 week MA | $1,218.8 | 17% above |
| 50 week MA | $1,102.2 | 29% above |
| 100 week MA | $954.1 | 50% above |
| 200 week MA | $797.5 | 79% above |
LLY has the edge over PAVM on trend strength, trading above more of its moving averages.
PAVM Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $2.37 | 43% below |
| 20 week MA | $3.97 | 66% below |
| 50 week MA | $6.56 | 80% below |
| 100 week MA | $12.0 | 89% below |
| 200 week MA | $59.1 | 98% below |
PAVM is in a downtrend: it's below all five of its weekly moving averages, and 98% below its 200-week average.
LLY Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $131.5 | $166.7 | +27% |
| 2021 | $166.7 | $273.1 | +64% |
| 2022 | $273.1 | $367.9 | +35% |
| 2023 | $367.9 | $582.9 | +58% |
| 2024 | $582.9 | $783.2 | +34% |
| 2025 | $783.2 | $1,077.8 | +38% |
| 2026 YTD | $1,077.8 | $1,427.3 | +32% |
LLY has the edge over PAVM on returns for 2026, with the stronger performance.
PAVM Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $517.5 | $877.5 | +70% |
| 2021 | $877.5 | $1,242.0 | +42% |
| 2022 | $1,242.0 | $227.3 | -82% |
| 2023 | $227.3 | $123.6 | -46% |
| 2024 | $123.6 | $19.4 | -84% |
| 2025 | $19.4 | $8.68 | -55% |
| 2026 YTD | $8.68 | $1.34 | -85% |
PAVM has finished four years in a row lower, and it's down 85% so far in 2026.